A headline on the Dublin markets report in Saturday's editions referred incorrectly to "patient fatalities" linked to pharmaceutical company Elan's multiple sclerosis (MS) drug Tysabri.
Elan's share price fell on Friday after it had announced that two more MS patients, who were taking Tysabri, had developed PML, a potentially fatal disease of the central nervous system. Elan's partner in the Tysabri programme, Biogen Idec, reported that one patient was clinically stable and is at home while the other was hospitalised.
